Literature DB >> 9652190

Therapeutic potential of histamine H3 receptor agonists and antagonists.

R Leurs1, P Blandina, C Tedford, H Timmerman.   

Abstract

The histamine H3 receptor was discovered 15 years ago, and many potent and selective H3 receptor agonists and antagonists have since been developed. Currently, much attention is being focused on the therapeutic potential of H3 receptor ligands. In this review, Rob Leurs, Patrizio Blandina, Clark Tedford and Henk Timmerman describe the available H3 receptor agonists and antagonists and their effects in a variety of pharmacological models in vitro and in vivo. The possible therapeutic applications of the various compounds are discussed.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9652190     DOI： 10.1016/s0165-6147(98)01201-2

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  20 in total

1.  Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis.

Authors:  A Chen; Z G Gao; D Barak; B T Liang; K A Jacobson
Journal:  Biochem Biophys Res Commun       Date:  2001-06-15       Impact factor: 3.575

2.  Cannabinoid CB(1) receptor-mediated inhibition of hippocampal acetylcholine release is preserved in aged mice.

Authors:  Agnes Redmer; Markus Kathmann; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

3.  Gastric antisecretory effects of compound BP 2-94: a histamine H3-receptor agonist prodrug.

Authors:  G Soldani; S Bertini; A Rouleau; J C Schwartz; G Coruzzi
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

4.  Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype.

Authors:  Kazuhiko Takahashi; Hiroaki Suwa; Tomoo Ishikawa; Hidehito Kotani
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

5.  Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure.

Authors:  T Nickel; U Bauer; E Schlicker; M Kathmann; M Göthert; A Sasse; H Stark; W Schunack
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology Study.

Authors:  Gunnar Flik; Joost H A Folgering; Thomas I H F Cremers; Ben H C Westerink; Eliyahu Dremencov
Journal:  J Mol Neurosci       Date:  2015-03-29       Impact factor: 3.444

7.  Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746.

Authors:  Jean-Dominique Gallezot; Beata Planeta; Nabeel Nabulsi; Donna Palumbo; Xiaoxi Li; Jing Liu; Carolyn Rowinski; Kristin Chidsey; David Labaree; Jim Ropchan; Shu-Fei Lin; Aarti Sawant-Basak; Timothy J McCarthy; Anne W Schmidt; Yiyun Huang; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

Review 8.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia.

Authors:  Y Chudasama; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

10.  Histamine induces Toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to Gram-positive and Gram-negative bacterial cell wall components.

Authors:  Jaya Talreja; Mohammad H Kabir; Michael B Filla; Daniel J Stechschulte; Kottarappat N Dileepan
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.